Approximately 25% of all cancers diagnosed each year are rare cancers. Despite this, the five-year survival rate for rare cancer patients is much lower than for those with non-rare cancers. This is why the Case Comprehensive Cancer Center (Case CCC) is kickstarting CURE (Conducting Unprecedented Research and Exploration): The Rare Cancer Initiative. Led by Case CCC Director Gary Schwartz, MD, the initiative builds on Case CCC’s collaborative nature, creating a national network among U.S. cancer centers and catalyzing innovative bench-to-bedside approaches to identify, treat, and, ultimately, defeat rare cancers.
Our goal is to raise $1 million a year for CURE in partnership with the Jed Ian Taxel Foundation for Rare Cancer Research (JEDI)—an organization founded by Mark and Linda Taxel in memory of their son Jed, who died from a rare cancer just six months after his diagnosis. CURE will fund cutting-edge research and therapies at Case CCC. We hope you will join the crusade to conquer rare cancer.
Together, we can transform cancer research and save lives worldwide.